Neue Therapiemöglichkeiten bei nichtalkoholischer Fettleber

Insulin resistance is a major pathophysiological factor in the development of non-alcoholic fatty liver disease. Moderate weight reduction und exercise are therefore recommended as a standard treatment in obese patients. Based on the results of large prospective randomized clinical trials, there is currently no strong evidence to recommend the routine use of pharmacologic treatment for non-alcoholic fatty liver disease. Non-invasive markers for assessing staging and grading in patients with non-alcoholic fatty liver disease are not available. Metformin and the thiazolidinediones have shown promise in pilot trials, but further controlled studies are needed. Vitamin E and ursodeoxycholic acid cannot be recommend based on current evidence.